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CURRENTOPINION Dopamine D2 up-regulation in psychosis patients
after antipsychotic drug treatment
Ilse A. Thompsona, Erik F.J. de Vriesb, and Iris E.C. Sommerc
Purpose of review
Recently, it has been questioned whether the re-emergence of psychotic symptoms following antipsychotic
discontinuation or dose reduction is attributable to underlying psychotic vulnerability or to rebound effects
of chronic use of antipsychotic medication. It was repeatedly shown that relapse rates are high after
discontinuation of maintenance treatment. A potential contributing factor could be the increase in density
of postsynaptic dopamine D2 receptors in the striatum and the higher affinity of D2 receptors for dopamine
after chronic blockade.
Recent findings
To date, little clinical evidence is available for the mechanisms involved in postsynaptic striatal D2 receptor
up-regulation after use of antipsychotic medication, and most knowledge comes from animal studies.
Summary
Further research is needed to investigate whether antipsychotic medication causes neuroadaptations
leading to a dopamine supersensitive state in humans, how long such hypersensitive states may last and
what differences exist between high and low D2 affinity antipsychotic drugs. Further, information is needed
on discontinuation schedules that provide optimal protection for relapse during hypersensitive periods.
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INTRODUCTION
Schizophrenia spectrum disorders are clinically
characterized by positive symptoms (e.g. hallucina-
tions and delusions), negative symptoms (e.g. moti-
vational impairment, social withdrawal and apathy)
and cognitive alterations (e.g. an inability to sustain
attention and poor executive functioning). Several
theories have tried to explain the onset of psychotic
symptoms, of which the dopaminergic theory is
the most accredited one. This theory states that a
complex dopaminergic dysregulation may underlie
the positive symptoms of schizophrenia [1]. Phar-
macotherapy with antipsychotic medication is the
standard treatment for patients who experience
psychosis, according to most national and inter-
national guidelines [2,3]. All antipsychotics act
downstream at the dopamine D2 receptors on
the postsynaptic terminals to reduce dopamine-
mediated signaling, which reduces psychotic symp-
toms. Chouinard et al. [4] proposed that chronic
use of antipsychotic medication may lead to com-
pensatory changes and a dopamine-sensitive state.
Dopamine (super)sensitivity (DSP) is the excessive
response to the (natural, or amphetamine-induced)
release of dopamine. DSP is characterized by the
rapid re-emergence of psychotic symptoms after
discontinuation or dose reduction of antipsychotic
medication, and subsequent tolerance to antipsy-
chotic treatment and eventually refractoriness [5].
A plausible explanation for (super)sensitivity to
aUniversity of Groningen, University Medical Center Groningen, Depart-
ment of Biomedical Sciences of Cells & Systems, Section of Cognitive
Neurosciences, bUniversity of Groningen, University Medical Center
Groningen, Department of Biomedical Sciences of Cells & Systems,
Section of Cognitive Neurosciences, Groningen and cUniversity of
Groningen, University Medical Center Groningen, Department of Bio-
medical Sciences of Cells & Systems, Section of Cognitive Neuro-
sciences, Groningen, the Netherlands
Correspondence to Ilse A. Thompson, MSc, University of Groningen,
University Medical Center Groningen, Department of Biomedical Scien-
ces of Cells & Systems, Cognitive Neurosciences, Groningen, the
Netherlands. E-mail: i.a.thompson@umcg.nl
Curr Opin Psychiatry 2020, 33:200–205
DOI:10.1097/YCO.0000000000000598
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the work
provided it is properly cited. The work cannot be changed in any way or
used commercially without permission from the journal.
www.co-psychiatry.com Volume 33  Number 3  May 2020
REVIEW
dopamine is the up-regulation of D2 receptor expres-
sion or an increase in the fraction of the receptors
that are in the high-affinity state [4]. In the time the
hypothesis was put forward, antipsychotic dosing
regimen tended to be a 10–20-fold higher than now.
However, this up-regulation may cause a potentially
supersensitive postsynaptic receptor system, which,
in combination with a presynaptic dopaminergic
system not being sufficiently suppressed, may
increase the risk of relapse after discontinuation.
Previous studies have indicated that the risk of
symptom recurrence was between 67 and 77%
one year after discontinuation, and had increased
to over 90% two years after discontinuation [6
&
,7].
Interestingly, the former study [6
&
] also investigated
whether the length of antipsychotic treatment
before discontinuation associated with risk of
relapse. The groups were divided into 12 months
or less of antipsychotic treatment (n¼42), and at
least 12 months treatment (n¼20). Interestingly, it
was noted that the duration of prior antipsychotic
treatment was not associated with a reduced risk of
relapse. However, other studies show an increase
risk of relapsing when discontinuing, as studies
show that patients who do not use antipsychotic
medication for a prolonged time are significantly
less likely to relapse [8,9]. These figures clearly issue
a warning against discontinuation of maintenance
therapy, as risk for recurrence of psychosis is high,
but they also indicate that recurrence rates become
even higher with prolonged exposure to antipsy-
chotics when discontinuing treatment. Thus, while
it is widely assumed that a psychotic episode follow-
ing antipsychotic discontinuation or dose reduction
is attributable to the underlying psychotic illness,
there have been concerns that discontinuation after
maintenance treatment may actually make patients
more vulnerable to psychotic relapse than would be
the case in the natural course of the illness without
antipsychotic treatment [10]. It is important to
emphasize that the validity of the DSP hypothesis,
namely an up-regulation of dopamine D2 receptors
provoked by chronic and long-term occupancy of
dopamine D2 receptors, leading to an increased den-
sity of postsynaptic dopamine D2 receptors in the
striatum, has not been fully proven yet, at least not in
clinical studies [11]. In this review, we will summarize
the evidence for and against this hypothesis.
ANIMAL STUDIES
A possible mechanism underlying DSP may be an
increased dopamine D2 receptor density in the stri-
atum. Several studies have shown that the chronic
administration of haloperidol indeed increased the
dopamine D2 receptor density in the striatum in
rodents [12
&&
,13–16]. The most recent study [12
&&
]
evaluated the effects of 21-day repeated administra-
tion of haloperidol at 1 mg/kg and brexpiprazole at
4 mg/kg on striatal dopamine D2 receptor density in
rats, and found that while haloperidol increased the
density, brexpiprazole showed no effect, compared
to vehicle treatment. This suggests that brexpipra-
zole may have a lower risk of increasing the D2
receptor density, and possible consequently relaps-
ing after repeated administration. A recent study
indeed shows fewer relapses in brexpiprazole com-
pared to cariprazine and lurasidone [17]. Another
recent study [13] compared blonanserin at 0.78 mg/
kg with haloperidol at 1.1 mg/kg twice daily for 28
days. The results showed an increased striatal dopa-
mine D2 receptor density in the rats treated with
haloperidol, whereas blonanserin did not show an
effect. This suggests that blonanserin is less likely to
induce an up-regulation of the dopamine D2 recep-
tor density as compared to haloperidol. Further-
more, aripiprazole at 10 mg/kg has been shown to
cause up-regulation of the dopamine D2 receptor
[18], although another study with a lower dose of
1.5 mg/kg did not show an up-regulation of the D2
receptors [16]. Olanzapine at 10 mg/kg has also been
shown to not increase the D2 receptors [15].
Moreover, the study by Amada et al. [12
&&
]
reported that the chronic treatment of risperidone
(1.5 mg/kg) significantly increased locomotor activ-
ity induced by apomorphone (0.1 mg/kg; P<0.01),
suggesting sensitized D2 receptors in rats after the
chronic treatmentof risperidone. The studybyHashi-
moto et al. [13] reported significantly enhanced
hyperlocomotion in rats treated with haloperidol,
whereas with blonanserin, the total hyperlocomo-
tion was not significantly different to vehicle-treated
rats. This suggests that blonanserin might be less
KEY POINTS
 There is no clear evidence for a relationship between
dopamine D2 receptor up-regulation and dopamine
supersensitivity psychosis (DSP) in schizophrenia
patients;
 Risk for relapse of psychosis is high, which may be
increased with prolonged exposure to antipsychotics;
 The potential mechanism behind high relapse rates, in
patients who discontinue antipsychotic medication after
maintenance treatment, may be D2 receptor up-
regulation;
 Further research is needed to determine whether
changes in dopamine neurotransmission are present in
patients after starting antipsychotic treatment.
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likely to induce DSP after chronic administration,
compared to haloperidol.
Another possible mechanism to underlie DSP is
the increase in number of dopamine D2
high receptors.
It is known that dopamine D2 receptors can exist in a
state of high-affinity (G-protein-coupled high-affin-
ity; D2




high is the functionally active state of
the dopamine D2 receptor [19]. While antipsychotic
medication may not elevate the density of dopamine
D2 receptors, it has been shown that they can increase
the number of dopamine D2
high receptors in animal
studies [20]. Although it should be noted that the
animals in this study were still being treated with
olanzapine when the analysiswas performed, with an
occupancy of approximately 70%. The study by
Samaha et al. [21] investigated presynaptic and post-
synaptic elements of the dopaminergic system dur-
ing ongoing treatment by measuring the ability of
haloperidol to inhibit amphetamine locomotion.
They found a tolerance to increase dopamine and
dopamine turnover presynaptically, while showing a
20–40% increase in D2 receptor number postsynap-
tically, and 100–160% increases in the proportion of
D2
high postsynaptically. These results suggest that
antipsychotic treatment may lose its efficacy related
to dopamine D2 receptor increase.
Another study [22] investigated whether contin-
uous or intermittent treatment induced amphet-
amine-induced locomotion in rats, as an indication
of antipsychotic-induced dopamine supersensitivity.
Haloperiodol was continuously or intermittently
administered for16–17 days.After3–5 days, amphet-
amine-induced locomotion was measured. The
results showed that only the rats with continuous
treatment showed enhanced amphetamine-induced
locomotion. It could be argued that continuous
treatment with antipsychotic drugs may cause
neuroadaptations, inducing supersensitive behavior,
whereas intermittent dosing is not associated with
such behavior [22,23]. This could be of clinical inter-
est, as present patient guidelines recommend 1-year
continuous antipsychotic treatment after an episode
of psychosis. It could be argued that some patients
benefit from continuous treatment, whereas it might
also promote neuroadaptations that could cause
dopamine supersensitivity. However, relapse rates
are shown to be high after 1–2 years of treatment
who are treated with depot antipsychotics (i.e. con-
tinuous treatment with high adherence).
CLINICAL STUDIES
Whereas animal studies have shown that chronic
administration of antipsychotic treatment can lead
to neuroadaptations, there are very few recent clini-
cal studies examining whether antipsychotic
medication plays a role in the up-regulation of
dopamine D2 receptors in humans, and whether
relapse following antipsychotic withdrawal is linked
to an up-regulation of dopamine D2 receptors. Clear
evidence that chronic exposure of antipsychotic
medication can lead to a ‘dopamine supersensitive
state’ is lacking [24].
Clinical studies investigating the role of
antipsychotic medication in neuroadaptations
The first clinical study [25] investigating the role of
antipsychotic medication in the up-regulation of
dopamine D2 receptors compared patients with
schizophrenia (n¼9) who had received long-term
antipsychotic treatment relative to antipsychotic-
naive patients with schizophrenia (n¼8). Patients
were treated with first-generation antipsychotics
(e.g. haloperidol, perhenazine) and second-genera-
tion antipsychotics (risperidone, olanzapine) in
moderate to high dosages. Fourteen days after drug
withdrawal, the binding potentials of dopamine D2
receptors were measured using positron emission
tomography (PET) using [11C]raclopride, a radioli-
gand of the dopamine D2/3 receptor antagonist.
Results showed that long-term treatment with anti-
psychotics were associated with a substantial
increase of 30% in D2 receptor binding in the stria-
tum. Another study[26] scanned eight antipsy-
chotic-naive patients with schizophrenia, using
[11C]-(þ)-PHNO PET – a radioligand of the dopa-
mine D2/3 receptor antagonist, to estimate dopa-
mine D2/3 receptor binding in patients. Patients
were scanned before treatment and after approxi-
mately 2.5 weeks of treatment of either olanzapine
at 10 mg/day or risperidone at 2–3 mg/day. Results
show that 40–45% of the D2/D3 receptors in the
caudate and putamen was occupied by the thera-
peutic drug (i.e. less receptor availability). The
authors suggest that this lower receptor availability
might be due to lower doses used in first episode
patients. Indeed, a small but significant elevation
in D2/D3 receptor availability has been found
in patients who use antipsychotic medication
(d¼0.26, P¼0.049) as compared to antipsychotic-
naı̈ve patients, although this finding is not consis-
tent across studies [27]. Moreover, when caudate
and putamen in treated patients were analyzed sep-
arately, no significant differences in D2/D3 receptor
availability were observed. Interestingly, the results
of the meta-analysis show that dopamine D2 recep-
tor density is unaltered in drug-naive patients before
antipsychotic medication, which suggests that
D2/D3 alterations are not intrinsic to the illness,
Schizophrenia and related disorders
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but may be secondary to chronic antipsychotic
treatment [27]. It has been suggested that 36–
39% of relapsed patients chronically treated with
antipsychotic medication show dyskinesia, sug-
gesting that these patients may be ‘supersensitive’
[28,29]. However, it should be noted that this study
associated abnormal involuntary moments (i.e.
dyskinesia) with D2 hypersensitivity, but did not
measure dopamine D2 receptor availability. Contra-
dictive to those results are the results of another
study [30] that found no differences between
patients discontinued after treatment with either
placebo (n¼97) or ongoing antipsychotic treat-
ment (n¼36) (paliperidone palmitate once
monthly). This clinical study was conducted to
compare the nature of relapse after either condi-
tion, in terms of onset and severity of psychotic
symptoms, the presence of tardive dyskinesia and
the relapse symptom profiles. Thus, the authors
state that the study found no evidence for with-
drawal-related phenomena contributing to high
relapse rates after the discontinuation of antipsy-
chotic medication.
Clinical studies investigating possible
biomarkers for the development of dopamine
supersensitivity psychosis
In a recent study [31
&
], first episode psychosis patients
(n¼25) were compared to healthy controls (n¼14)
to investigate whether dopaminergic function
changes after the discontinuation of antipsychotic
medication. At baseline patients started tapering off
medication, and at 4 weeks patients completed taper-
ing off. The participants completed two [18F]FDOPA
PET scans: at baseline (i.e. prediscontinuation) and
after 6 weeks of treatment (i.e. 2 weeks postdiscon-
tinuation), and a [11C]raclopride PET scan at 7 weeks.
The results showed no significant difference between
relapsed and nonrelapsed patients in dopamine D2
availability, although a trend towards significance
was observed (P¼0.055). Furthermore, relapsing
patients showed an increase in dopamine synthesis,
compared to nonrelapsing patients. This is in line
with previous research, suggesting that relapse may
be associated with presynaptic abnormalities instead
of with postsynaptic D2 availability or dopamine
transporters [27]. The authors suggest that relapsed
patients could be different in the underlying patho-
physiology [31
&
]. Therefore, dopamine synthesis
measured using PET could possibly be used for the
prediction of relapse after discontinuing antipsy-
chotic medication in a first episode of psychosis,
by validating dopamine synthesis as a possible bio-
marker. Another recent study by Kanahara et al. [32]
investigated the possible biomarker CYP2D6 – one of
the most important drug-metabolizing enzyme,
which is suggested to be involved in dopamine super-
sensitivity. CYP2D6 may be a possible biomarker, as
patients with an impaired allele may have higher
concentrations of the antipsychotic and its active
metabolite. Thirty-six patients were divided in two
groups: one with normal metabolizing activity and
the other with lower activity of its variant. The con-
centrations of risperidone and 9-OH-risperidone
were measured in blood samples. The results showed
that no effect of the enzyme, or metabolism on
relapse could be detected. DSP may be associated
with D2
high, but not with the total D2 receptor den-
sity, as an increase in D2
high receptors without signif-
icant increases in dopamine D2 receptors have been
observed in an animal model by Seeman [33]. A
recent study by Kubota et al. [34] indicated a higher
proportion of D2
high in the putamen of drug-naı̈ve
(n¼10)/drug-free (n¼1) patients with schizophrenia
as compared to healthy controls, despite the total
amount of dopamine D2 receptors being unaltered.
This is in line with Chouinard et al. [35], who pro-
posed that the chronic use of antipsychotics may
increase the total number of dopamine D2 receptors
and dopamine D2
high receptors in the striatum, with-
out showing significant changes in the presynaptic
dopamine release, synthesis,or reuptake. Theauthors
hypothesized that the increase inD2 receptorsenhan-
ces D2-medicated dopamine signaling, which produ-
ces a state of supersensitivity to stimulation of a
dopamine agonist. This could lead to DSP. How-
ever, it is not clear whether this effect is caused by
antipsychotic treatment, as the studies by Kubota
et al. [34] and Seeman [33] found, enhanced high-
affinity D2 receptor density in patient and animal
models without antipsychotic treatment. To date,
only a limited number of studies investigated
whether alterations exist in the amount of D2
high
or in the proportion of D2
high ligand binding in
patients with schizophrenia [34], and there is no
evidence yet about the effect of drug discontinua-
tion on the affinity state of D2 receptors. High
relapse rates have been associated with antipsy-
chotic treatment resistance [36
&&
], as it has been
shown that antipsychotic dose is significantly
higher in patients after a second episode of psycho-
sis [36
&&
]. However, it could be argued that this may
actually be the up-regulation of dopamine D2 recep-
tors, as the animal model by Samaha et al. [21]
demonstrated a reduced efficacy after long-term
administration of antipsychotic medication, which
could be partly compensated by an increase in drug
dose. Furthermore, the studies showed that both
the concentration of D2 receptors and the fraction
of receptors in the high-affinity state were signifi-
cantly increased when resistance occurred.
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CONCLUSION
While it is widely assumed that the re-emergence
of psychotic symptoms following antipsychotic
discontinuation (or reduction) is attributable to
the underlying psychotic vulnerability, relapse risk
may partly be caused by receptor up-regulation
after chronic antipsychotic use. There is sparse
clinical evidence for dopamine supersensitivity,
but stronger evidence from animal studies. Anti-
psychotic drugs with lower D2 blockade, such as
the partial agonist aripiprazole, lower dose and
intermittent treatment, seem to reduce this risk
[16]. Thus, maintenance therapy at the lowest
possible dose is needed to obtain clinical stability,
as risk for symptom recurrence after withdrawal is
very high. When patients want to discontinue
antipsychotic medication, tapering off should
be performed over prolonged time (3–6 months)
and under regular supervision. A previous study
showed that in FEP patients this was feasible in
only 20% [37]. Because antipsychotic medication
is the mainstay of treatment in psychosis, a greater
understanding of dopamine up-regulation and its
prevention may greatly affect patient outcomes.
To date, little clinical evidence is available for the
mechanisms involved in postsynaptic striatal D2
receptor up-regulation and the influence of anti-
psychotic medication. Therefore, new clinical
studies are needed to investigate whether changes
in dopamine neurotransmission are present in
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